^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    UGT1A1*1*1

    i
    Other names: UGT1A1, UDP glucuronosyltransferase family 1 member A1, GNT1, UGT1, UDPGT, UGT1A, HUG-BR1, BILIQTL1, UDPGT 1-1
    Entrez ID:
    54658
    Related biomarkers:
    Mutation
    1year
    Protein abundance of drug transporters and drug-metabolizing enzymes in paired healthy and tumor tissue from colorectal cancer patients. (PubMed, Int J Pharm)
    Other proteins of interest which could be quantified in colonic samples were the drug transporters P-gp, MRP3, MRP4, OATP2B1, MCT1 and enzymes CYP4F2, CYP2J2 and UGT1A1. The insights from this study enhance our understanding of the extent to which drug disposition in tumor tissue of colorectal cancer patients could be impacted by drug transporters and drug-metabolizing enzymes and may facilitate a more accurate prediction of local drug concentrations.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • ABCC3 (ATP Binding Cassette Subfamily C Member 3) • SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17)
    |
    UGT1A1*1*1
    1year
    Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=25 --> 2 | Trial primary completion date: Dec 2026 --> Jan 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH1 R132 • UGT1A1*1*1
    |
    cytarabine • Tibsovo (ivosidenib) • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    1year
    Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels (PubMed, Yakugaku Zasshi)
    Additionally, CYP and UGT expression levels may possibly affect cancer prognosis by metabolizing endogenous substrates, regardless of their role in anti-cancer drug metabolism. In this review, I discuss CYP and UGT expression level profiles in RCC based on previously published papers, including ours, and examine possible relationships between these enzyme expression profiles and treatment outcomes for patients with RCC.
    Review • Journal • IO biomarker
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    |
    UGT1A1*1*1
    1year
    Construction and validation of prognosis and treatment outcome models based on plasma membrane tension characteristics in bladder cancer. (PubMed, PeerJ)
    In addition, some drugs such as cisplatin, paclitaxel, doxorubicin, and docetaxel exhibited lower IC50 values in the high MTRG score group. Our study sheds light on the prognostic significance of MTRGs within the TME and their correlation with immune infiltration patterns, ultimately impacting patient survival in BLCA. Notably, our findings highlight DCBLD2 as a promising candidate for targeted therapeutic interventions in the clinical management of BLCA.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • FOSL1 (FOS Like 1) • IGFBP3 (Insulin-like growth factor binding protein 3) • HTRA1 (HtrA Serine Peptidase 1)
    |
    UGT1A1*1*1
    |
    cisplatin • paclitaxel • docetaxel • doxorubicin hydrochloride
    1year
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    1year
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (clinicaltrials.gov)
    P2, N=60, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    1year
    Pharmacogenetics of colorectal cancer in a third-level hospital in Valencia. (PubMed, Adv Lab Med)
    The population frequencies obtained in our study for rs1801160 and rs75017182 (DPYD); and for *1/*28, *28/*, and *1/*36 (UGT1A1) were inconsistent with the frequencies reported for the Spanish population in the literature. The genotypes CT of rs1801160, AT of rs67376798 (DPYD), and 1/*36 (UGT1A1) were associated with lower survival rates.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    UGT1A1*1*1
    1year
    Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=34, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Nov 2024 | Trial primary completion date: May 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    Opdivo (nivolumab) • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    1year
    MP-VAC-203: Phase 1b/2a, Open-label Study of Vactosertib in Combination with Durvalumab in Advanced NSCLC (clinicaltrials.gov)
    P1/2; Phase classification: P1b/2a --> P1/2 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Oct 2022 --> May 2024
    Combination therapy • Trial completion date • Trial primary completion date • Phase classification • Metastases
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    PD-L1 expression • UGT1A1*1*1
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • vactosertib (TEW-7197)
    1year
    Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial. (PubMed, JAMA Netw Open)
    To date, the clinical benefit and utility of implementing a DPYD/UGT1A1 pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan have not been prospectively investigated...Clinical benefit did not appear to be affected. ClinicalTrials.gov Identifier: NCT03093818.
    Clinical • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    irinotecan
    1year
    Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial. (PubMed, Clin Transl Sci)
    PGx screening and prescribing were feasible in routine oncology care and improved patient outcomes. Findings may inform expanded PGx programs within cancer and other disease settings.
    Clinical • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    irinotecan
    1year
    Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Jul 2025
    Enrollment closed • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1
    |
    Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium